ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
REGENXBIO Inc

REGENXBIO Inc (RGNX)

11.69
-0.81
(-6.48%)
Closed September 20 4:00PM
11.69
0.00
( 0.00% )
Pre Market: 4:00AM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.508.5011.509.2010.000.000.00 %015-
5.005.109.000.007.050.000.00 %00-
7.502.706.500.004.600.000.00 %00-
10.001.204.501.702.850.000.00 %03-
12.500.251.301.400.7750.000.00 %0328-
15.000.200.800.290.500.000.00 %0343-
17.500.201.200.300.700.000.00 %016-
20.000.231.300.230.7650.000.00 %036-
22.500.263.900.262.080.000.00 %069-
25.000.424.600.422.510.000.00 %012-
30.000.194.600.192.3950.000.00 %08-
35.000.554.600.552.5750.000.00 %01-
40.001.003.101.002.050.000.00 %021-

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.004.600.000.000.000.00 %00-
5.000.000.250.000.000.000.00 %00-
7.500.004.600.000.000.000.00 %00-
10.000.403.500.401.950.000.00 %013-
12.500.902.050.801.4750.000.00 %0270-
15.002.855.202.994.0250.000.00 %0275-
17.504.807.505.906.150.000.00 %035-
20.007.7010.007.658.850.000.00 %054-
22.508.5012.505.5010.500.000.00 %03-
25.0011.0014.9013.4012.950.000.00 %08-
30.0016.0020.000.0018.000.000.00 %00-
35.0021.0024.800.0022.900.000.00 %00-
40.0026.0030.200.0028.100.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUKKNukkleus Inc
$ 0.3604
(69.60%)
13.79M
SOXMTradr 2X Long SOXX Monthly ETF
$ 36.96
(58.98%)
44
LGCBLinkage Global Inc
$ 0.6354
(51.90%)
9.32M
NVVENuvve Holding Corporation
$ 5.62
(43.37%)
732.37k
LGHLWLion Group Holding Ltd
$ 0.008
(33.33%)
12
PRFXPainReform Ltd
$ 0.59
(-23.49%)
15.68k
ZJYLJin Medical International Ltd
$ 3.20
(-21.57%)
21.54k
SMXTSolarMax Technology Inc
$ 0.7029
(-19.75%)
200
ADTXAditxt Inc
$ 0.3101
(-18.95%)
58.13k
CJETChijet Motor Company Inc
$ 2.28
(-18.57%)
750
NUKKNukkleus Inc
$ 0.3604
(69.60%)
13.79M
LGCBLinkage Global Inc
$ 0.6472
(54.72%)
9.32M
MAXNMaxeon Solar Technologies Ltd
$ 0.0776
(-15.19%)
3.23M
GSIWGarden Stage Ltd
$ 1.63
(21.64%)
2.99M
INTCIntel Corporation
$ 22.61
(3.53%)
1.76M

RGNX Discussion

View Posts
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
πŸ‘οΈ0
Zmill Zmill 5 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
πŸ‘οΈ0
BlackEyePatch BlackEyePatch 5 years ago
Strong buy @ 50!!!!
πŸ‘οΈ0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Hope no more form 4s for insider selling
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Let’s see how tomorrow will be
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
$45 soon! Yummy
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

πŸ‘οΈ0
protagonist12 protagonist12 8 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
πŸ‘οΈ0
floWteiuQ floWteiuQ 8 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
πŸ‘οΈ0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock